An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
A phase 3 trial of Ivosidenib in biliary tract cancer, run by Servier Affaires Médicales, active and no longer recruiting.
Overview
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma is a phase 3 interventional study registered as NCT05876754 by Servier Affaires Médicales, with 299 participants enrolled, started 2023-05-03 and due to reach its primary completion in 2027-12-01. Interventions recorded: Ivosidenib Oral Tablet.
Similar pages
not linked directly; found by shared links- TrialIvosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Shares Ivosidenib and the tag pipeline.
- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Shares Ivosidenib and the tag pipeline.
- TrialPhase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialCombination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.